Preeclampsia is a severe complication of pregnancy. Antiangiogenic factors soluble fms-like
tyrosine kinase-1 (sFlt-1) and soluble endoglin are secreted in excess from the placenta, …

Background Preterm preeclampsia has a high rate of fetal death or disability. There is no
treatment to slow the disease, except delivery. Preclinical studies have identified proton pump …

Fetal growth restriction (FGR) is a major obstetric complication stemming from poor placental
development. We have previously demonstrated that paternal obesity in mice is associated …

Preeclampsia is a disease of pregnancy associated with placental oxidative stress,
inflammation and elevated release of anti-angiogenic factors sFlt-1 and soluble endoglin. These …

Preeclampsia is a hypertensive disorder of pregnancy characterized by maternal endothelial
dysfunction and end-organ damage. The antiangiogenic factor, sFlt-1 (soluble FMS-like …

Objectives Soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng) are the
most studied molecules in preeclampsia. However, most trophoblast cell lines do not secrete …

Preeclampsia is a complex disease affecting 2–8% of pregnancies worldwide. It poses
significant risk of maternal and perinatal morbidity and mortality. Despite the rising research …

Background Fetuses affected by placental insufficiency do not receive adequate nutrients
and oxygenation, become growth restricted and acidemic, and can demise. Preterm fetal …

Introduction The discovery of new treatments that prevent or treat preeclampsia would be a
major advance. Antiangiogenic factors soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble …

Preeclampsia affects ∼2–8% of pregnancies worldwide. It is associated with increased long-term
maternal cardiovascular disease risk. This study assesses the effect of the …